The government can, however, ask the manufacturers to continue producing a required level of essential drugs in public interest, according to the Drug Price Control Order, (DPCO) 2013.
"Any manufacturer of scheduled formulations, intending to discontinue any scheduled formulation from the market shall issue a public notice and also intimate the Government...In this regard at least six months prior to the intended date of discontinuation," the order said.
Also Read
The DPCO 2013, which would replace DPCO 1995, is most likely to be notified by the government in April.
"Government may in public interest direct the manufacturer of the scheduled formulation to continue with required level of production and/or export as specified in the order for a period not exceeding one year from the intended date of such discontinuation within 60 days of receipt of such intimation," the DPCO said.
Further, drug makers will have to maintain records relating to the sales of APIs (Active Pharmaceutical Ingredients) and bulk drugs, manufactured or imported.
"The government shall have the power to call for any record or to inspect such records at the premises of the manufacturer," says DPCO, 2013.
Price control over drugs was first introduced in the country in the aftermath of the Chinese aggression by the Drugs (Display of Prices) Order 1962 and the Drugs (Control of Prices) Order 1963.
The drug policy of 1994 covers 74 bulk drugs under price control and it was implemented through DPCO 1995.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)